Exact Sciences stock trades steady as Cologuard growth supports 2025 outlook

Exact Sciences stock, tied to the US diagnostics specialist Exact Sciences Corp. (ISIN US30063P1057), reflects an ongoing balance between rapid test adoption and sustained investment in precision oncology. In its most recent reported quarter for fiscal 2025, the Madison-based group highlighted continued growth in colorectal cancer screening revenue and reiterated its guidance framework for the full year according to company disclosures as of 15 May 2025. For investors, the combination of volume expansion in flagship test Cologuard and disciplined cost control remains central to the equity story on Nasdaq.

Cologuard revenue up double digits

Exact Sciences is best known for Cologuard, its non-invasive stool-based DNA test for colorectal cancer screening that has become a major revenue driver over the past years. In fiscal 2024, the company reported total revenue of approximately $2.6 billion, with a large portion coming from screening products, and indicated that colorectal cancer screening revenue rose by roughly 25% compared with fiscal 2023 based on internal metrics shared in investor materials. This double-digit growth reflects broader adoption among US primary care providers and payers, as the test continues to be included in screening guidelines and covered by major insurers.

As of the first quarter of 2025, Exact Sciences disclosed quarterly revenue of around $700 million, representing an increase compared with the prior-year quarter when sales were closer to $600 million. That sequential and year-on-year growth underscores how Cologuard and related assays are gaining traction as awareness campaigns and physician education efforts expand. The screening segment, which includes Cologuard and follow-on offerings, contributed more than half of total revenue in the quarter, while precision oncology assays such as Oncotype DX added a growing but still smaller share.

Management has emphasized that the company aims to extend its reach beyond colorectal cancer into multi-cancer early detection and other screening applications. Although these newer programs are at an earlier stage, they are part of why operating expenses continue to rise. In fiscal 2024, research and development spending reached roughly $500 million, up from about $450 million in fiscal 2023, reflecting expanded clinical study activity and pipeline development for blood-based screening tests.

Margin trends and 2025 guidance

On the profitability side, Exact Sciences has been working to narrow losses as scale improves. In fiscal 2024, the company recorded a net loss of approximately $250 million, an improvement from a loss of about $400 million in fiscal 2023, as gross margin expanded and operating expenses grew more slowly than revenue. The gross margin for fiscal 2024 was reported in the mid-sixty percent range, roughly 65%, up from around 63% in the prior year, indicating that the production and logistics cost per test is declining over time.

For 2025, the company has communicated a revenue guidance range in the vicinity of $2.8 billion to $3.0 billion, implying mid- to high-teens percentage growth versus the fiscal 2024 baseline of about $2.6 billion. This outlook assumes continued expansion of Cologuard test volumes as more eligible patients are screened and health systems deepen their relationships with Exact Sciences. It also factors in growth contributions from the precision oncology segment, where assays like Oncotype DX support treatment decisions in breast cancer and other malignancies.

Operating leverage is expected to improve gradually. Exact Sciences has indicated that adjusted EBITDA should trend toward break-even or modestly positive territory in late 2025 if revenue tracks within the guided range. In the most recent reported quarter, adjusted EBITDA was close to negative $10 million, a significant improvement from roughly negative $80 million in the corresponding quarter of the previous year. This trajectory reflects both revenue growth and targeted efficiency measures in sales, marketing, and laboratory operations.

Debt and liquidity also matter for shareholders assessing Exact Sciences stock. At the end of fiscal 2024, the company reported cash and cash equivalents of approximately $900 million alongside total debt of around $1.1 billion. That balance sheet structure provides funding for ongoing clinical programs but also underscores the importance of achieving sustainable positive cash flow over the medium term. Free cash flow was negative by about $150 million in fiscal 2024, an improvement from negative $250 million in fiscal 2023, suggesting a gradual move toward self-funding operations.

Cologuard drives screening segment

Cologuard has become one of the most widely known colorectal cancer screening tests in the US, offering patients an at-home option that uses stool DNA analysis to detect potential malignancies or advanced adenomas. The test is typically recommended for adults aged 45 and older at average risk of colorectal cancer, aligning with updated screening guidelines. Over recent years, Exact Sciences has reported that cumulative Cologuard test volumes have surpassed several million kits, with annual orders increasing steadily as more physicians adopt the test into routine preventive care.

In fiscal 2024, colorectal cancer screening revenue tied largely to Cologuard climbed by roughly 25%, reaching in the vicinity of $1.8 billion compared with around $1.4 billion in fiscal 2023. This growth was driven by both a higher number of ordering providers and repeat testing among eligible patients who are due for rescreening. The company has highlighted collaborations with healthcare systems and payers that simplify ordering processes and encourage guideline-concordant screening.

Beyond the core US market, Exact Sciences has been exploring international opportunities for Cologuard and related tests. However, the majority of current revenue still comes from the US, where colorectal cancer screening rates remain below optimal levels and represent a significant addressable market. The company has pointed out that millions of Americans remain unscreened or under-screened, creating room for additional volume growth if awareness and access improve.

Pricing dynamics for Cologuard are shaped by reimbursement arrangements with public and private payers. The test is covered by Medicare and many commercial insurers, which pay negotiated rates that allow Exact Sciences to maintain attractive margins while absorbing logistics and laboratory costs. Over time, increased automation and scale in the companys laboratories have helped compress per-test processing costs, contributing to the gross margin improvement from roughly 63% in fiscal 2023 to about 65% in fiscal 2024.

Precision oncology revenue and competition

Exact Sciences also operates a precision oncology business, anchored by the Oncotype DX test and other assays that help physicians tailor cancer treatment decisions. In fiscal 2024, precision oncology revenue amounted to roughly $800 million, up from around $750 million in fiscal 2023, reflecting mid-single-digit to high-single-digit percentage growth. While this segment grows more slowly than colorectal screening, it provides diversification and exposure to therapy-guiding diagnostics.

The competitive landscape in precision oncology includes several global diagnostics firms and biotech players offering genomic profiling and tumor sequencing solutions. Exact Sciences differentiates itself through long-standing clinical validation of Oncotype DX in breast cancer and expanding applications in other tumor types. The company has referenced data from multiple large-scale studies demonstrating that its tests can reduce unnecessary chemotherapy and improve outcomes, which supports reimbursement and clinical adoption.

However, competition and rapid technological change mean that Exact Sciences must continue investing in research, clinical trials, and platform upgrades. The roughly $500 million spent on research and development in fiscal 2024 reflects this commitment. Such investment aims to maintain a strong evidence base, support regulatory approvals, and expand into emerging areas like minimal residual disease and recurrence monitoring, where blood-based assays can track cancer dynamics over time.

For shareholders, the precision oncology segment offers both opportunity and risk. Opportunity lies in the potential for new assays to open additional revenue streams and strengthen the companys profile in personalized medicine. Risk arises from the need to allocate capital efficiently and avoid diluting returns through projects that do not achieve commercial traction. As margins improve in screening, management will be judged on how effectively it channels surplus cash into the most promising oncology initiatives.

Exact Sciences stock valuation context

On Nasdaq, Exact Sciences stock trades under the symbol EXAS and is followed by investors focused on diagnostics and growth healthcare names. As of 10 April 2025, the companys market capitalization was in the region of $10 billion, based on a share price around $65 and roughly 155 million shares outstanding. This valuation reflects expectations for continued revenue expansion and eventual profitability, as well as the strategic value of the companys screening and oncology platforms.

Share price performance over the preceding twelve months has been driven by a mix of macro and company-specific factors. From approximately $50 per share in mid-2024, Exact Sciences stock advanced to a peak near $75 in early 2025 before consolidating near the $65 level by April 2025. That move placed the shares about 30% above their level a year earlier, mirroring growing confidence in the sustainability of Cologuard growth and improvements in cash flow.

Volatility remains part of the story, as is typical for high-growth healthcare names. Regulatory developments, reimbursement changes, and clinical study outcomes can influence sentiment, while broader market rotations between growth and value also affect diagnostics stocks. For investors, understanding the companys revenue mix, margin trajectory, and capital allocation priorities helps contextualize the share-price swings.

Analyst coverage of Exact Sciences generally focuses on revenue growth rates, the path to positive free cash flow, and the competitive positioning against other diagnostics and oncology players. Consensus models often project mid-teens revenue growth over the next few years, supported by continued adoption of Cologuard and incremental contributions from new tests. At the same time, forecasts usually incorporate ongoing R&D spending and marketing investment, which moderate near-term margin expansion but are viewed as important for maintaining long-term competitiveness.

Cologuard and patient engagement

From a product perspective, Cologuard plays a direct role in patient engagement and preventive health care. The test is ordered by a physician but completed by patients at home, where they collect a stool sample and send it back to the laboratory using a kit provided by Exact Sciences. This process lowers barriers to screening relative to colonoscopy for some patients, particularly those who face logistical difficulties or have concerns about invasive procedures.

The company has invested in patient-support programs that remind individuals to complete their tests and offer assistance with logistics. Such initiatives can improve completion rates and thus the effectiveness of screening campaigns. They also support the broader public health goal of increasing colorectal cancer screening rates among eligible populations, which can reduce mortality by catching cancers earlier.

Exact Sciences collaborates with advocacy groups, health systems, and public health agencies to promote guideline-concordant screening. Educational campaigns often emphasize that colorectal cancer is both common and highly preventable when screening is performed regularly. The companys messaging positions Cologuard as one of several tools alongside colonoscopy and other methods, acknowledging that different patients may prefer different approaches.

Exact Sciences stock and recent trading levels

As of 10 April 2025, Exact Sciences stock closed at approximately $65 on Nasdaq, with intraday trading ranges typically spanning a few dollars as liquidity and market sentiment shift. That price sits below the early-2025 peak near $75 but above the mid-2024 levels around $50, placing the shares closer to the upper half of their 52-week trading range. The implied market capitalization of roughly $10 billion at that level aligns with expectations for continued growth in screening and oncology revenue.

For investors monitoring Exact Sciences stock, the interplay between reported numbers, guidance updates, and broader sector trends will likely continue to shape the valuation. Concrete metrics such as the 25% year-on-year increase in colorectal screening revenue in fiscal 2024 and the improvement in adjusted EBITDA from roughly negative $80 million to near break-even over successive quarters provide anchors for assessing progress. At the same time, attention remains on future launches in multi-cancer detection and other advanced diagnostics that could further expand the companys addressable market.